Alk-Abelló A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1923-01-01

Employees: -

Market Cap: $5.8B

Website: http://www.alk.net/

Clinical Trials

Impact of AIT on Allergic Rhinitis and Asthma

Completed

Conditions: Allergy
Respiratory Disease

Interventions: Drug: Allergy immunotherapy (AIT)

First Posted Date: 2019-10-14

Last Posted Date: 2021-06-02

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 92048

Registration Number: NCT04125888

Locations: 🇩🇰
ALK Abelló, Hørsholm, Denmark

N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

Completed

Conditions: Allergic Rhinitis Due to House Dust Mite
Allergic Asthma Due to Dermatophagoides Farinae
Allergic Asthma Due to Dermatophagoides Pteronyssinus

First Posted Date: 2018-11-20

Last Posted Date: 2021-05-17

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 1508

Registration Number: NCT03746860

Locations: 🇫🇷
Hôpital Arnaud de Villeneuve, Montpellier, France

Mite Asthma Pediatric Immunotherapy Trial

Phase 3

Completed

Conditions: Allergic Asthma Due to Dermatophagoides Farinae
Allergic Asthma Due to Dermatophagoides Pteronyssinus
Allergic Rhinitis Due to House Dust Mite

Interventions: Biological: HDM SLIT-tablet
Other: Placebo

First Posted Date: 2018-08-31

Last Posted Date: 2023-10-19

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 533

Registration Number: NCT03654976

Locations: 🇧🇬
Alitera-Med-Medical Center EOOD, Sofia, Bulgaria
🇵🇱
Specjalistyczna Praktyka Lekarska, Katowice, Poland
🇪🇸
Hospital Universitario Vall d'Hebrón, Barcelona, Spain

and more 61 locations

A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber

Phase 2

Completed

Conditions: Allergic Rhinoconjunctivitis

Interventions: Drug: SQ tree SLIT-tablet
Drug: Placebo

First Posted Date: 2015-06-25

Last Posted Date: 2017-01-19

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 219

Registration Number: NCT02481856

Locations: 🇨🇦
Inflamax Research Inc., Mississauga, Ontario, Canada

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Phase 4

Completed

Conditions: Allergic Rhinoconjunctivitis

Interventions: Drug: GRAZAX

First Posted Date: 2015-05-08

Last Posted Date: 2018-01-17

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 58

Registration Number: NCT02437786

Locations: 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Phase 4

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Biological: MK-3641 12 Amb a 1-U (short ragweed extract)
Biological: MK-7243 2800 BAU (Timothy grass extract)
Drug: Rescue Medication

First Posted Date: 2014-10-03

Last Posted Date: 2017-03-03

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 102

Registration Number: NCT02256553

Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber

Phase 2

Completed

Conditions: Grass Pollen Induced Allergic Rhinoconjunctivitis

Interventions: Drug: AVANZ Phleum pratense 15,000 SQ+
Drug: Placebo

First Posted Date: 2014-06-18

Last Posted Date: 2016-01-26

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 140

Registration Number: NCT02166268

Locations: 🇩🇪
Fraunhofer Institute, Hannover, Germany

An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy

Phase 2

Completed

Conditions: Allergic Rhinoconjunctivitis

Interventions: Biological: AVANZ Cupressus

First Posted Date: 2014-02-24

Last Posted Date: 2015-01-06

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 52

Registration Number: NCT02069535

Locations: 🇪🇸
Hospital Clinico Universitario San Carlos, Madrid, Spain

An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

Phase 2

Completed

Conditions: Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen

Interventions: Biological: AVANZ Salsola

First Posted Date: 2014-02-19

Last Posted Date: 2015-01-14

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 51

Registration Number: NCT02065856

Locations: 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain

Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate

Phase 4

Completed

Conditions: Allergic Rhinitis Due to Grass Pollens

Interventions: Other: Placebo
Drug: Grazax

First Posted Date: 2013-05-15

Last Posted Date: 2017-06-28

Lead Sponsor: ALK-Abelló A/S

Target Recruit Count: 51

Registration Number: NCT01854736

Locations: 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy